Source: FIERCE MEDICAL DEVICES

Xhale: Startup submits novel biomarker for clinical trial medication adherence tracking to FDA

Proteus Digital Health and Otsuka submitted the first medication to incorporate adherence technology to the U.S. Food and Drug Administration for approval last week. Now, startup Xhale has submitted the first biomarker for medication adherence monitoring to the regulatory agency. Proteus obtained an FDA nod specifically for its medication adherence technology in July.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Douglas M. Crumb's photo - President & CEO of Xhale

President & CEO

Douglas M. Crumb

CEO Approval Rating

75/100

Read more